Corvus Pharmaceuticals Granted U.S. Patent Titled ‘Methods of treating cancer’
https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=11040040.PN.&OS=PN/11040040&RS=PN/11040040
BioCryst Pharmaceuticals Granted U.S. Patent Titled ‘Open-label Berotralstat Access to HAE Patients Previously Enrolled in Berotralstat Studies (APeX-A)’
https://clinicaltrials.gov/ct2/show/NCT04933721
EXFO Granted U.S. Patent Titled ‘CLAIM The ornamental design for a display screen or portion thereof with graphical user interface, as shown and described.’
https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=5522&f=G&l=50&d=PTXT&p=111&S1=20210622&OS=20210622&RS=20210622
Adial Pharmaceuticals Shares Spike Higher; Co Says Plans To Enter Genetic Testing Market Following Allowance Of U.S. Patent For Genetic Diagnostic Test
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL, ADILW)))), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced plans
Sorrento Therapeutics Granted U.S. Patent ‘Receptacle portion of transdermal drug delivery apparatus and methods’
https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=4614&f=G&l=50&d=PTXT&p=93&S1=20210622&OS=20210622&RS=20210622
Eastman Kodak Granted U.S. Patent Titled ‘Photosensitive compositions containing silver ion a-oxy carboxylate-oxime complexes’
https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=3728&f=G&l=50&d=PTXT&p=75&S1=20210622&OS=20210622&RS=20210622
Novan Granted U.S. Patent Titled ‘Topical antiviral compositions, delivery systems, and methods of using the same’
https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=4790&f=G&l=50&d=PTXT&p=96&S1=20210622&OS=20210622&RS=20210622
Exelixis 8-K Shows. Co. Received Notice Letters From Teva Related To Abbreviated New Drug Application For CABOMETYX Tablets; Co. Filed Complaint In US For Patent Infringement Against Teva
In May 2021, Exelixis, Inc. (“Exelixis”) received notice letters from Teva Pharmaceuticals USA, Inc. and Teva Pharmaceuticals Development, Inc. (collectively, “Teva”) regarding an Abbreviated New
Synaptogenix Shares Quiet, See Volume Spike As Traders Circulate US Patent & Trademark Office Application For Co.’s ‘METHODS FOR INDUCING SYNAPTOGENESIS WITH SYNAPTIC GROWTH FACTOR ACTIVATING COMPOUNDS’
https://patentcenter.uspto.gov/#!/applications/16914399